Boehringer Ingelheim struck an agreement with the U.S. administration to join the TrumpRx.gov purchasing platform and pledged $10 billion in U.S. investments through 2028 to expand R&D and manufacturing. The deal includes exemption from potential Section 232 tariffs and commitments to lower medicine prices for American patients via direct purchasing arrangements. Boehringer emphasized the move as a step to improve supply chain resilience and patient access, while the White House framed the agreement as part of a broader strategy to secure domestic manufacturing and negotiate lower prices. The arrangement may set a template for future pharma‑government pacts that combine onshoring investments with pricing concessions.